Yamaguchi Kanji

ヤマグチカンジ | Yamaguchi Kanji

Affiliation and department：
Job title： Associate professor

Research field (2)： Gastroenterology , Medical biochemistry

Research keywords (3)：代謝学 , 消化器病学 , 肝臓病学

Research theme for competitive and other funds (10)：

2022 - 2025 Significance of Apg-2 in human NAFLD
2022 - 2025 The role of heat shock protein Apg-2 in hepatic lipogenesis and hepatocarcinogenesis by using liver organoids.
2019 - 2022 The role of heat shock protein Apg-2 in hepatic lipogenesis and hepatocarcinogenesis by the inhibition of lipophagy
2016 - 2019 The role of HSP110 family, Apg-2 in NASH-related hepatic lipid and glucose metabolism.
2015 - 2018 The role of Apg-2 in liver steatosis and carcinogenesis

Show all

Papers (197)：

Yuya Seko, Kanji Yamaguchi, Toshihide Shima, Saiyu Tanaka, Takao Shirono, Yusuke Takahashi, Kento Takeuchi, Seita Kataoka, Michihisa Moriguchi, Takeshi Okanoue, et al. Prognostic performance of a two-step method using the Fibro-Scope system for metabolic dysfunction-associated steatotic liver disease. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
Kento Takeuchi, Kanji Yamaguchi, Yusuke Takahashi, Kota Yano, Shinya Okishio, Hiroshi Ishiba, Nozomi Tochiki, Seita Kataoka, Hideki Fujii, Naoto Iwai, et al. Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction. Scientific reports. 2024. 14. 1. 23993-23993
Yuya Seko, Kanji Yamaguchi, Toshihide Shima, Michihiro Iwaki, Hirokazu Takahashi, Miwa Kawanaka, Saiyu Tanaka, Yasuhide Mitsumoto, Masato Yoneda, Atsushi Nakajima, et al. Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease. Liver international : official journal of the International Association for the Study of the Liver. 2024
Ayana Fujiwara, Keisuke Takemura, Anna Tanaka, Misaki Matsumoto, Masato Katsuyama, Takeshi Okanoue, Kanji Yamaguchi, Yoshito Itoh, Kazumi Iwata, Kikuko Amagase, et al. Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation. Scientific reports. 2024. 14. 1. 19288-19288
Michihisa Moriguchi, Keiichiro Okuda, Go Horiguchi, Seita Kataoka, Yuya Seko, Kanji Yamaguchi, Takeshi Nishimura, Hideki Fujii, Yasuhide Mitsumoto, Masami Miyagawa, et al. Safety/efficacy of atezolizumab + bevacizumab during anti-platelet/anticoagulation therapy in unresectable hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver. 2024

ｍore...

MISC (200)：

森田竜一, 森田竜一, 石川剛, 石川剛, 石川剛, 榊田智喜, 榊田智喜, 榊田智喜, 片岡星太, 三宅隼人, et al. C-CATデータから見る,日本人における特殊型膵がんのゲノムプロファイリング-臨床的特徴についての検討も含めて-. 日本遺伝性腫瘍学会学術集会プログラム・抄録集. 2023. 29th
片岡星太, 楳村敦詩, 瀬古裕也, 山口寛二, 森口理久, 伊藤義人. 膵臓における変化がNASH発癌に与える影響. 肝臓. 2023. 64. Supplement 1
楳村敦詩, 片岡星太, 奥田佳一郎, 瀬古裕也, 山口寛二, 森口理久, 伊藤義人. NASH疫学とリスク因子-NAFLD/NASH : epidemiology and risk factors-特集 NAFLD/NASH診療up-to-date. 消化器・肝臓内科 = Gastroenterology & hepatology / 消化器・肝臓内科編集委員会編. 2021. 10. 2. 204-209
山口寛二, 瀬古裕也, 伊藤義人. 肝臓病学の未来-ウイルス性肝炎から脂肪肝と肝がんの時代へ NAFLD/NASH 糖尿病治療のインパクト. 内科. 2019. 123. 5. 1137-1141-1141
伊藤義人, 山口寛二, 楳村敦詩, 西川太一朗, 瀬古裕也. Biomarkers/Scoring Systems of NAFLD/NASH. 日本臨床. 2019. 77. 5. 806-811

ｍore...

Professional career (1)：

M.D. & Ph.D. (Kyoto Prefectural University of Medicine)

Association Membership(s) (2)：

日本内科学会 , 日本肝臓学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page